This content is from: Premium
The New Hedge Fund That Surged 200 Percent in 2020
Suvretta Capital affiliate Averill posted eye-popping returns, while Suvretta posted very strong gains of its own.
Averill, the new biopharmaceutical fund managed by a team under the Suvretta Capital umbrella, posted blowout returns for its first partial year of trading, according to a communication sent to clients and seen by Institutional Investor.Averill, which manages about $350 million and began trading on March 23, gains between 195
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.